Statins Combined with AAV8-TBG-LOX-1 Reduce the Vascular Lipid-driven Inflammatory Response and Inhibit Atherosclerosis

This study shows that combining statins with #AAV8 TBG #LOX1 holds promise for reducing lipid-driven #Inflammation, limiting #Macrophage deposition & inhibiting #Atherosclerosis, offering a new target for treatment in #CardiovascularDisease. #medsky
Read: doi.org/10.1007/s115...

This #MostRead review discusses the applications & challenges of using #AAV8 as a vector for #GeneTherapy, highlighting the biological properties that make it a promising candidate vector for efficient #GeneTransfection. #medsky
#OpenAccess:
www.sciencedirect.com/science/arti...

REGENXBIO INITIATES TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

REGENXBIO INITIATES TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

RGX-202 microdystrophin expression results in ambulatory patients aged 8+ are the highest reported microdystrophin levels across approved or investigational gene therapies.

Source: regenxbio.gcs-web.com/news-release...

#dmd #regenxbio #RGX202 #AFFINITYDUCHENNE #AAV8